HSN Leadership  

Cynthia I. Campbell, PhD, MPH​

Health System Node Principal Investigator
Kaiser Permanente Division of Research

 

Dr. Cynthia Campbell is a Senior Research Scientist at the Kaiser Permanente Northern California Division of Research​, where she is Co-Director of the Center on Addiction and Mental Health Research and conducts research on the treatment of substance use disorder (SUD) and mental health problems. She is also an Adjunct Associate Professor in the Department of Psychiatry, University of California, San Francisco​ and at the Kaiser Permanente Bernard J. Tyson School of Medicine. Her interests include access to SUD treatment, SUD among patients with pain, prescription opioid use and misuse, and organizational factors and policy related to these areas. She has led NIH and PCORI funded studies on the impact of the ACA legislation on addiction and HIV services, on substance use service intensity for buprenorphine patients, and a trial of a patient activation intervention in primary care for chronic pain patients using prescription opioids. Currently, she is the Principal Investigator of the CTN-0084, a prescription opioid registry developed across 10 health system, and MPI of CTN-0084-A-2, a feasibility study examining how to use digital health tools to continuously collect data on patients with opioid use disorder being treated with buprenorphine. She is a co-investigator on CTN-0074, the PROUD Trial, and CTN-0077, a study of how patients document medical cannabis use in their health record.  Her work also includes th​e study of attention deficit hyperactivity disorder (ADHD) in children and young adults. She received her doctorate in Public Health at the University of Michigan, and conducted her postdoctoral work at UCSF in a NIDA-funded fellowship on Substance Abuse and Health Services. Dr. Campbell was recently funded to lead CTN-0117​, which will use EHR data to examine the major shift to virtual treatment for drug use disorders during the pandemic in a large, diverse health care system, specifically exploring potential disparities in accessing treatment.

 

 

Ingrid A. Binswanger, MD, MPH, MS

Health System Node Principal Investigator
Kaiser Permanente Colorado Institute for Health Research​

 

Dr. Ingrid A. Binswanger is a Senior Clinician Investigator at the Institute for Health Research, Kaiser Permanente Colorado. She is also a Professor of Medicine at the University of Colorado School of Medicine and Adjunct Professor of Health Systems Science at the Kaiser Permanente Bernard J. Tyson School of Medicine. Dr. Binswanger's research focuses on preventing overdose, improving treatment provision and outcomes in health systems, and improving healthcare transitions between carceral and community settings.  Her prior work includes practice-changing studies on death after release from prison, pragmatic trials of strategies to enhance naloxone provision in health systems, and multisite studies of the intended and unintended effects of opioid tapering and discontinuation. After a decade of involvement in the NIDA CTN Health Systems Node as Site PI for Kaiser Permanente Colorado, she joined the Health Systems Node leadership team as Multiple PI in 2025. She is currently a site lead for Insurance Instability and Mortality (CTN-0141) and site PI for Office-based Methadone Trial - EMBOSS (CTN-0131). She was Co-I on the following completed CTN studies: HEDIS AOD-IET Measure Performance (CTN-0072), Evaluation of Medical Cannabis Documentation (CTN-0077), Prescription Opioid Registry (CTN-0084), and Determining Optional Duration of Buprenorphine Treatment (CTN-0084-A-1). And she was site PI for an exemplar site of the PROUD trial (CTN-0074). Dr. Binswanger is dual board-certified in internal medicine and addiction medicine. As a physician with the Colorado Permanente Medical Group, she sees patients in the Rapid Start Clinic, Chemical Dependency Treatment Services at Kaiser Permanente Colorado. ​​

​ 

 

 

Katharine A. Bradley, MD, MPH

Health System Node Principal Investigator
Kaiser Permanente Health Research Institute

 

Dr. Katharine Bradley is a general internist and Senior Investigator at Kaiser Permanente Washington Health Research Institute​. She conducts health services research and pragmatic and implementation trials focused on improving the quality of care for patients with unhealthy alcohol and substance use in general medical settings.  She previously conducted extensive research validating and implementing AUDIT-C alcohol screening questionnaire in the VA.  Recently she led the NIAAA-funded CHOICE trial that tested the effectiveness of collaborative care for alcohol use disorders in the VA (completed in 2017) and the SPARC trial, a pragmatic stepped-wedge trial to implement evidence-based care for unhealthy alcohol use in Kaiser Permanente Washington (KPWA).  Dr. Bradley currently leads the PROUD trial (CTN-0074), which is which is a pragmatic trial testing a collaborative care model for treating opioid use disorders (OUDs) in primary care across 6 diverse health systems.  She is also Multiple PI on two other pragmatic trials: an NIMH-funded HEAL project that includes a pragmatic trial of patient-centered, collaborative care for primary care patients with OUD and depression in KPWA and Indiana University Health System (MI-CARE trial; MPI with Dr. Debar), and an AHRQ-funded implementation trial of evidence-based alcohol-related care across 125 primary care clinics in Michigan (MI-SPARC trial; MPI with Anya Day at Altarum in Michigan), based on lesson from the SPARC trial.  Recent health services research studies included CTN-0065, which evaluated a pilot study implementing cannabis and other drug screening in 3 primary care sites (completed 2018), and CTN-0077 (MPI with Dr. Lapham) that is studying how patients use cannabis to manage symptoms and how that is documented in their electronic health records (EHRs).  Dr. Bradley was recently funded to lead CTN-0113 with Dr. Williams, which will use EHR data to evaluate the psychometric performance of a DSM-5 substance use symptom checklist in the context of routine primary care. 

​ ​

. 

Core Investigators

Core investigators are supported by the HSN and bring a breadth of expertise and leadership to concept and protocol development. Our core investigators bring expertise in leading trials, statistical methods, and qualitative methods.

• Stacy Sterling, DrPH, MSW, MPH
• Joshua Nugent, PhD
• Andrea Altschuler, PhD
• Gwen Lapham, PhD, MPH, MSW
• Jennifer Bobb, PhD
• Marlaine Figueroa Gray, PhD
• Jason Glanz, PhD
• Komal Narwaney, PhD
• Anh Nguyen, PhD
  
  

Affiliate investigators include additional senior investigators who can lead CTN trials, mid-career investigators with important expertise to support CTN trials, and early-stage investigators who will be mentored and collaborate in executing Node agendas. Many are embedded within affiliate health systems.